2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

PC-3 prostate cancer cells

" in MedChemExpress (MCE) Product Catalog:

45

Inhibitors & Agonists

4

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-122678
    LQZ-7F

    		Survivin Apoptosis Cancer
    LQZ-7F, a survivin dimerization inhibitor, induces spontaneous apoptosis and synergizes with Docetaxel in prostate cancer cells. LQZ-7F dose-dependently inhibits survival of both PC-3 and C4-2 cells with IC50s of 2.99 and 2.47 µM, respectively .
    LQZ-7F
  • HY-130709
    PROTAC CDK2/9 Degrader-1

    		PROTACs CDK Cancer
    PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 µM) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand .
    PROTAC CDK2/9 Degrader-1
  • HY-12364
    C75
    20+ Cited Publications

    		 Fatty Acid Synthase (FASN) Cancer
    C75 is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    C75
  • HY-107640
    WAY-170523

    		MMP Cancer
    WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC50 of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research .
    WAY-170523
  • HY-147854
    B-Raf IN 9

    		Raf Apoptosis Cancer
    B-Raf IN 9 (compound 8b) is a potent B-Raf inhibitor, with an IC50 of 24.79 nM. B-Raf IN 9 induces apoptosis and shows cell cycle arrest at G2/M phase. B-Raf IN 9 exhibits potent antitumor activity against human prostate cancer PC-3 cell line, with an IC50 of 7.83 µM .
    B-Raf IN 9
  • HY-121619
    Jacaric acid

    		Apoptosis Inflammation/Immunology Cancer
    Jacaric acid is a conjugated linolenic acid, which inhibits viability in cells PC-3 (IC50 is 11.8 μM), LNCaP (IC50 is 2.2 μM) and DLD-1, induces apoptosis and necrosis . Jacaric acid exhibits anticaner activity against prostate cancer and adenocarcinoma . Jacaric acid exhibits immunomodulating activity in murine peritoneal macrophages as an immunopotentiator . Jacaric acid is orally active.
    Jacaric acid
  • HY-147853
    B-Raf IN 8

    		Raf Cancer
    B-Raf IN 8 (compound 7g) is a potent B-Raf inhibitor, with an IC50 of 70.65 nM. B-Raf IN 8 exhibits antitumor activity against hepatocellular carcinoma (HEPG-2), colon carcinoma (HCT-116), mammary gland (MCF-7) and human prostate cancer (PC-3) cells, with IC50 values of 9.78, 13.78, 18.52 and 29.85 µM .
    B-Raf IN 8
  • HY-147852
    B-Raf IN 7

    		Raf Cancer
    B-Raf IN 7 (compound 6a) is a potent B-Raf inhibitor, with an IC50 of 110.23 nM. B-Raf IN 7 exhibits antitumor activity against colon carcinoma (HCT-116), mammary gland (MCF-7), hepatocellular carcinoma (HEPG-2), human cervical carcinoma (Hela) and human prostate cancer (PC-3) cells, with IC50 values of 7.50, 9.87, 10.57, 11.63 and 12.83 µM .
    B-Raf IN 7
  • HY-147100
    α1A-AR Degrader 9c

    		PROTACs Adrenergic Receptor Cancer
    α1A-AR Degrader 9c (compound 9c) is a potent, selective and reversible α1A-AR (Adrenergic receptor) PROTAC degrader, with a DC50 of 2.86 μM. α1A-AR Degrader 9c induces α1A-AR degradation can be attributed to proteasomal degradation. α1A-AR Degrader 9c inhibits the proliferation of PC-3 cells, with an IC50 of 6.12 μM. α1A-AR Degrader 9c shows antitumor activity, and can be used for prostate cancer research .
    α1A-AR Degrader 9c
  • HY-149976
    Pim-1 kinase inhibitor 4

    		Pim Cancer
    Pim-1 kinase inhibitor 4 (Compound 10f) is a Pim-1 kinase inhibitor (IC50: 17.01 nM). Pim-1 kinase inhibitor 4 also has antioxidant activity and inhibits DPPH. Pim-1 kinase inhibitor 4 induces apoptosis in PC-3 cell, and inhibits PC-3 cell growth with an IC50 of 16 nM. Pim-1 kinase inhibitor 4 can be used for research of prostate cancer .
    Pim-1 kinase inhibitor 4
  • HY-12842
    UC-112

    		IAP Apoptosis Cancer
    UC-112 is a novel potent IAP(Inhibitor of apoptosis) inhibitor; potently inhibit cell growth in two human melanoma (A375 and M14) and two human prostate (PC-3 and DU145) cancer cell lines(IC50=0.7-3.4 uM).
    UC-112
  • HY-153910
    AGPS-IN-1

    		Others Cancer
    AGPS-IN-1 (Compound 2i) is an effective AGPS binder. AGPS-IN-1 reduces ether lipids levels and cell migration rate. AGPS-IN-1 inhibits epithelial-mesenchymal transition (EMT) in prostate PC-3 and breast MDA-MB-231 cancer cells .
    AGPS-IN-1
  • HY-103385
    NCX4040

    NO-Aspirin

    		 Apoptosis Inflammation/Immunology Cancer
    NCX4040 (NO-Aspirin), a non-steroidal anti-inflammatory drug (NSAID), is a nitric oxide (NO) releasing form of Aspirin. NCX4040 induces apoptosis in PC3 metastatic prostate cancer cells. NCX4040 has anti-inflammatory and anti-cancer effects .
    NCX4040
  • HY-147734
    Calpain Inhibitor-2

    		Others Cancer
    Calpain inhibitors are lipophilic and show moderate to good antiproliferative activity in vitro compared with melanoma cell lines (a-375 and b-16f1) and PC-3 prostate cancer cells. In addition, a member of this group (compound 3) expressed 2 μ M concentration inhibited the invasion of DU-145 cells by 80%.
    Calpain Inhibitor-2
  • HY-155610
    VEGFR-2-IN-32

    		VEGFR Cancer
    VEGFR-2-IN-32 (Comp 3a) is an inhibitor of VEGFR-2 with an IC50 of 8.93 nM. VEGFR-2-IN-32 has cytotoxic activity against PC-3 cells with an IC50 of 1.22 μM. VEGFR-2-IN-32 can be used for anti-prostate cancer research .
    VEGFR-2-IN-32
  • HY-12364B
    (−)-C75

    		Fatty Acid Synthase (FASN) Cancer
    (−)-C75 is a isoform of C75 (HY-12364), which is a synthetic fatty-acid synthase (FASN) inhibitor; inhibits prostate cancer cells PC3 with an IC50 of 35 μM . C75 is a potent CPT1A activator .
    (−)-C75
  • HY-125010
    Dicycloplatin

    		DNA/RNA Synthesis Apoptosis Cancer
    Dicycloplatin is a DNA damage inducer. Dicycloplatin induces DNA damage by activating biphosphorylated checkpoint kinase 2 (CHK2), breast cancer 1 (BRCA1) and triphosphorylated p53. Dicycloplatin can induce cell cycle arrest, inhibit proliferation and lead to apoptosis in prostate cancer PC3 cells and lung cancer NCI/H446 cells. Dicycloplatin can be used in cancer researchr .
    Dicycloplatin
  • HY-146170
    Anticancer agent 69

    		Reactive Oxygen Species EGFR Apoptosis Cancer
    Anticancer agent 69 (Compound 34), a potent and selective anticancer agent , potently and selectively inhibits human prostate cancer cell line PC3 (IC50=26 nM). Anticancer agent 69 increases ROS level, down-regulates EGFR and induces apoptosis .
    Anticancer agent 69
  • HY-138633
    PROTAC BRD4 Degrader-10

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-10 (compound 8b) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-10 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 1.3 nM and 18 nM, respectively .
    PROTAC BRD4 Degrader-10
  • HY-138632
    PROTAC BRD4 Degrader-9

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-9 (compound 8a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-9 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.86 nM and 7.6 nM, respectively .
    PROTAC BRD4 Degrader-9
  • HY-138555
    PROTAC BRD4 Degrader-8

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-8 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.1 nM and 1.4 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-8 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
    PROTAC BRD4 Degrader-8
  • HY-138634
    PROTAC BRD4 Degrader-11

    		PROTACs PROTAC-Linker Conjugates for PAC Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-11 (compound 9a) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-11 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.23 nM and 0.38 nM, respectively .
    PROTAC BRD4 Degrader-11
  • HY-138635
    PROTAC BRD4 Degrader-12

    		PROTACs PROTAC-Linker Conjugates for PAC Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-12 (compound 9c) is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. PROTAC BRD4 Degrader-12 can be conjugated with STEAP1 and CLL1 antibodies to degrade the BRD4 protein in PC3 prostate cancer cells, with a DC50 of 0.39 nM and 0.24 nM, respectively .
    PROTAC BRD4 Degrader-12
  • HY-138637
    PROTAC BRD4 Degrader-14

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-14 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 1.8 nM and 1.7 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-14 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
    PROTAC BRD4 Degrader-14
  • HY-139294
    PROTAC BRD4 Degrader-15

    		PROTACs Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-15 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4, with IC50s of 7.2 nM and 8.1 nM for BRD4 BD1 and BD2, respectively. PROTAC BRD4 Degrader-15 is capable of potently degrading the BRD4 protein in PC3 prostate cancer cells .
    PROTAC BRD4 Degrader-15
  • HY-158310
    SOS1/EGFR-IN-1

    		EGFR Ras Cancer
    SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM) .
    SOS1/EGFR-IN-1
  • HY-155718
    fac-[Re(CO)3(L6)(H2O)][NO3]

    		Apoptosis Cancer
    fac-[Re(CO)3(L6)(H2O)][NO3] (compound 6), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L6)(H2O)][NO3] is cytotoxic to prostate cancer cells, IC50=50 nM (PC-3 cells). fac-[Re(CO)3(L6)(H2O)][NO3] mainly accumulates in the nucleus, down-regulates ATP production in PC3 cells, and promotes apoptosis. However, fac-[Re(CO)3(L6)(H2O)][NO3] did not induce necrosis, pyrodeath and autophagy .
    fac-[Re(CO)3(L6)(H2O)][NO3]
  • HY-16160
    Cysmethynil

    		Autophagy ICMT Cancer
    Cysmethynil is an Icmt inhibitor(IC50 = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .
    Cysmethynil
  • HY-155719
    fac-[Re(CO)3(L3)(H2O)][NO3]

    		Paraptosis Cancer
    fac-[Re(CO)3(L3)(H2O)][NO3] (compound 3), the rhenium(I) tricarbonyl aqua complex, is an anticancer agent associated with mitochondrial dysfunction. fac-[Re(CO)3(L3)(H2O)][NO3] is cytotoxic to prostate cancer cells with IC50=0.32 μM (PC-3 cells). fac-[Re(CO)3(L3)(H2O)][NO3] mainly accumulates in mitochondria, down-regulates ATP production in PC3 cells, and promotes paraptosis. However, fac-[Re(CO)3(L3)(H2O)][NO3] did not induce necrosis, apoptosis and autophagy .
    fac-[Re(CO)3(L3)(H2O)][NO3]
  • HY-157404
    Pim-1/2 kinase inhibitor 2

    		Pim Cancer
    Pim-1/2 kinase inhibitor 2 (compound 5b) is a competitive PIM-1 and PIM-2 kinase inhibitor with IC50s of 1.31 μM and 0.67 μM, respectively. Pim-1/2 kinase inhibitor 2 shows in-vitro low cytotoxicity against normal human lung fibroblast Wi-38 cell line and potent in-vitro anticancer activity against myeloid leukaemia (NFS-60), liver (HepG-2), prostate (PC-3), and colon (Caco-2) cancer cell lines .
    Pim-1/2 kinase inhibitor 2
  • HY-138636
    PROTAC BRD4 Degrader-13

    		PROTAC-Linker Conjugates for PAC Epigenetic Reader Domain Cancer
    PROTAC BRD4 Degrader-13 (compound 9d) is a von Hippel-Lindau system-based PROTAC BRD4 degrader with a linker that can be coupled to ADC antibodies to form PACs (PROTAC-antibody Conjugates). PROTAC BRD4 Degrader-13 can be coupled to STEAP1 and CLL1 antibodies to degrade BRD4 protein in PC3 prostate cancer cells with DC50 values ​​of 0.025 nM and 6.0 nM, respectively .
    PROTAC BRD4 Degrader-13
  • HY-147696
    SMTIN-T140

    		HSP AMPK Reactive Oxygen Species Cancer
    SMTIN-T140 (compound 6a) is a potent TRAP1 (tumor-necrosis-factor-receptor associated protein 1) inhibitor, with an IC50 of 1.646 μM. SMTIN-T140 shows anticancer activity. SMTIN-T140 leads to mitochondrial dysfunction, increases mitochondrial ROS production and activates AMPK. SMTIN-T140 potently suppressed tumor growth without any noticeable in vivo toxicity in a mouse model xenografted with PC3 prostate cancer cells .
    SMTIN-T140
  • HY-N12983
    β-Bourbonene

    		Apoptosis Bcl-2 Family Cancer
    β-Bourbonene is a kind of sesquiterpene. β-Bourbonene inhibits cell growth, and induces apoptosis and G0/G1 arrest of prostate cancer PC-3M cells .
    β-Bourbonene
  • HY-W748509
    Pipernonaline

    		Caspase Apoptosis Cancer
    Pipernonaline is a piperine derivative with antiprostate cancer activity. Pipernonaline inhibits the proliferation of androgen-dependent/independent LNCaP/PC-3 prostate cells. Pipernonaline activates caspase-3 and promotes procaspase-3/PARP cleavage. Pipernonaline also mediates reactive oxygen species (ROS) production, increased intracellular Ca(2+), and mitochondrial membrane depolarization .
    Pipernonaline
  • HY-N12606
    Neodidymelliosides A

    		Fungal Infection
    Neodidymelliosides A (compound 1)It is a secondary metabolite of fungi and has a significant inhibitory effect on Staphylococcus aureus and Candida albicans biofilms. Neodidymelliosides AIt also has anti-cancer activity and can inhibit KB3.1 (cervix),PC-3 (prostate),MCF-7(breast),SKOV-3 (ovary),A431 (skin )and A549 (lung )Cell viability of cell lines .
    Neodidymelliosides A
  • HY-149091
    KDM5B-IN-4

    		Others Cancer
    KDM5B-IN-4 (compound 11ad) is a lysine demethylase 5B (KDM5B) inhibitor with an IC50 of 0.025 μM KDM5B-IN-4 increases substrate H3K4me1/2/3 level by inhibiting KDM5B in PC-3 cells. KDM5B-IN-4 downregulates PI3K/AKT. KDM5B-IN-4 reduces tumor volume in mice and shows less toxic to organs .
    KDM5B-IN-4
  • HY-120736
    MEB55

    		Others Cancer
    MEB55 is an antitumor agent. MEB55 shows anti-proliferative activity. MEB55 has the potential for the research of prostate cancer .
    MEB55
  • HY-146396
    Anticancer agent 51

    		Others Cancer
    Anticancer agent 51 (compound 3d) is a potent anticancer agent with an Ki of 731.62 nM. Anticancer agent 51 shows anticancer activity. Anticancer agent 51 has the potential for the research of prostate cancer .
    Anticancer agent 51
  • HY-118798
    DA 3003-2

    NSC663285

    		 Phosphatase Cancer
    DA 3003-2 is a potent and selectively Cdc25 inhibitor. DA 3003-2 shows antiproliferative activity. DA 3003-2 induces cell cycle arrest at the G2/M phase and increases the expression of P-tyr 15 Cdc2. DA 3003-2 has the potential for the research of prostate cancer .
    DA 3003-2
  • HY-163062
    Tubulin/NRP1-IN-1

    		Microtubule/Tubulin Apoptosis Complement System Cancer
    Tubulin/NRP1-IN-1 (compound TN-2) is a dual inhibitor of Tubulin and NRP1 with IC50s of 0.71 and 0.85 μM, respectively. Tubulin/NRP1-IN-1 significantly inhibits the viability of prostate tumor cell lines and induces apoptosis .
    Tubulin/NRP1-IN-1
  • HY-123295
    HDAC3-IN-T247

    		HDAC Infection Cancer
    HDAC3-IN-T247 is a potent and selective HDAC3 (histone deacetylase 3) inhibitor, with an IC50 of 0.24 µM. HDAC3-IN-T247 induces a selective increase of NF-κB acetylation in HCT116 cells. HDAC3-IN-T247 shows anticancer and antiviral activity. HDAC3-IN-T247 inhibits growth of cancer cells, and activates HIV gene expression in latent HIV-infected cells .
    HDAC3-IN-T247
  • HY-146433
    Anticancer agent 55

    		Apoptosis Cancer
    Anticancer agent 55 is a potent anticancer agent. Anticancer agent 55 shows anticancer activity via reducing the cell viability and cell migration in a dose-dependent manner. Anticancer agent 55 induces apoptosis. Anticancer agent 55 has the potential for the research of prostate cancer and breast cancer .
    Anticancer agent 55
  • HY-13610
    N1,N11-Diethylnorspermine

    		Caspase Cancer
    N1,N11-Diethylnorspermine (DENSPM) is a potent anticancer agent. N1,N11-Diethylnorspermine is a spermine analog that activates polyamine catabolism. N1,N11-Diethylnorspermine induces the release of cytochrome c from mitochondria, resulting in activation of caspase 3. N1,N11-Diethylnorspermine kills glioblastoma multiforme (GBM) cells through induction of SSAT (spermidine/spermine N1-acetyltransferase) coupled with H2O2 production .
    N1,N11-Diethylnorspermine
  • HY-163340
    GA32

    		Glucocorticoid Receptor Androgen Receptor Cancer
    GA32 (compound 58r) is potent androgen receptor (AR)/glucocorticoid receptor (GR) dual inhibitor with IC50 values of 0.13 μM and 0.83 μM for AR and GR, respectively. GA32 inhibits the proliferation of Enzalutamide (HY-70002) resistance castration-resistant prostate cancer both in vitro and in vivo .
    GA32
  • HY-161618
    MJ04

    		JAK EGFR PI3K IGF-1R GSK-3 Inflammation/Immunology Endocrinology
    MJ04 is a selective inhibitor for Janus Kinase 3 (JAK 3) with an IC50 of 2.03 nM. MJ04 inhibits T cell differentation and inhibits the proinfammatory cytokines in Lipopolysaccharides (HY-D1056)‑induced macrophages. MJ04 exhibits good pharmacokinetic characters in mice, promotes hair growth in DHT-induced androgenetic alopecia (AGA) in athymic mice model, without significant toxicity (LD50 >2 g/kg) .
    MJ04

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: